Document is current
Any future updates will be listed below
-
Authors
Parikh, Neehar D.
Girvan, Allicia
Coulter, Joshua
Gable, Jonathon
Poon, Jiat Ling
Kim, Sangmi
Chatterjee, Anindya
Boeri, Marco
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
- License Information
-
More Information
Article History
Received: 4 March 2022
Accepted: 30 November 2022
First Online: 19 January 2023
Declarations
:
: The study was reviewed and deemed exempt by the RTI International institutional review board. All patients provided informed consent to participate. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: NDP has served as a consultant for Bristol Myers-Squibb, Exact Sciences, Eli Lilly, and Freenome; has served on advisory boards of Genentech, Eisai, Bayer, Exelixis, Wako/Fujifilm; and has received institutional research funding from Bayer, Target RWE, Exact Sciences, Genentech, and Glycotest. JC and MB are full-time employees of RTI Health Solutions, an independent nonprofit research organization, which was retained by Eli Lilly and Company to conduct the research that is the subject of this manuscript. Their compensation is unconnected to the studies on which they work. JLP, SK, and AC are employees of Eli Lilly and Company and hold shares and/or stock options in the company. AG and JG were employees of Eli Lilly and Company at the time this study was conducted.
